CTT Pharmaceutical (CTTH) CEO reports open-market purchase of 1,800 shares

Rhea-AI Filing Summary

CTT Pharmaceutical Holdings, Inc. (CTTH), reporting as CEO, purchased 1,800 shares of its common stock on 2026-08-14 in an open-market or private transaction at $0.062 per share. Following this transaction, the reporting holder directly owns 9,355,456 shares of CTTH.

Insider Trade Summary

Net Buyer: 1,800 shares

Net Buy 1 txn

Insider CTT PHARMACEUTICAL HOLDINGS, INC.

Role CEO

Bought 1,800 shs ($111.60)

Type	Security	Shares	Price	Value
Purchase	CTTH	1,800	$0.062	$111.60

Holdings After Transaction: CTTH — 9,355,456 shares (Direct)

Key Figures

Shares purchased: 1,800 shares Purchase price: $0.062 per share Shares owned after transaction: 9,355,456 shares +1 more

4 metrics

Shares purchased 1,800 shares Non-derivative purchase on 2026-08-14, transaction code P

Purchase price $0.062 per share Price for the 1,800 CTTH shares acquired

Shares owned after transaction 9,355,456 shares Direct ownership following the reported purchase

Net buy shares 1,800 shares Net buy-sell direction in this Form 4 filing

FAQ

What insider transaction did CTTH report on this Form 4?

CTT Pharmaceutical Holdings, Inc. reported a purchase of 1,800 CTTH shares on 2026-08-14 at $0.062 per share, recorded as an open-market or private transaction and held as direct ownership.

How many CTTH shares were bought in the latest insider trade?

The reporting holder bought 1,800 CTTH shares. This single transaction was classified as a purchase in an open market or private transaction and increased the directly owned share balance reported on the Form 4.

What price was paid per share in the recent CTTH insider purchase?

The insider purchase was executed at $0.062 per share. This price applies to the 1,800 shares acquired in the reported non-derivative transaction on 2026-08-14 under transaction code "P."

What is the total CTTH shareholding after this insider transaction?

After the transaction, the reporting holder directly owns 9,355,456 CTTH shares. This figure reflects the updated balance following the 1,800-share purchase disclosed in the Form 4 filing for the non-derivative security.

Was the CTTH insider trade made under a Rule 10b5-1 trading plan?

The filing indicates the Rule 10b5-1 checkbox is not affirmed (set to false). This means the reported 1,800-share purchase was not designated in the form as being made under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/14/2026 - 05:24 PM Accepted by SEC EDGAR 08/14/2026 - 05:24 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CTT PHARMACEUTICAL HOLDINGS, INC.

(Last) (First) (Middle)

1646 W. SNOW AVE SUITE 138

(Street)

TAMPA FLORIDA 33606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CTT PHARMACEUTICAL HOLDINGS, INC. [ CTTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
CTTH	08/14/2026		P		1,800	A	$0.062	9,355,456	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	Ryan Khouri	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)